EQL Pharma AB (publ) Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
EQL Pharma AB (publ) Stock Forecast and Price Target
Given the average yearlong price target of kr23.48 provided by prominent analysts over the past few months, there is a potential downside of approximately -45.01% from the last closing price in April, 2024 for EQL Pharma AB (publ)'s stock if it is reached. This estimation is based on a high estimate of kr26.29 and a low estimate of kr20.89. If you are not interested in EQL stock, you may be interested in its competitors.
-45.01% Downside
EQL Pharma AB (publ) Fair Value Forecast for 2023 - 2025 - 2030
In the last year, EQL Pharma AB (publ)'s Price has fallen from kr32.25 to kr0.00 – a 100.00% decrease. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach kr46.95 – an increase of 100.00%. Over the next six years, experts anticipate that Fair Value growth for EQL Pharma AB (publ) will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CAMX Stock Forecast | Camurus AB (publ) | Outperform |
6
|
kr485.00 | Buy/Sell | kr471.33 | 21.65% |
| RECI B Stock Forecast | Recipharm AB (publ) | - |
15
|
kr232.00 | Buy/Sell | kr232.00 | -100.00% |
| BIOG B Stock Forecast | BioGaia AB (publ) | Buy |
18
|
kr119.50 | Buy/Sell | kr115.00 | 17.15% |
| SECARE Stock Forecast | Swedencare AB (publ) | Outperform |
16
|
kr55.00 | Buy/Sell | kr50.00 | 23.64% |
| CALTX Stock Forecast | Calliditas Therapeutics AB (pu... | Outperform |
10
|
kr100.50 | Buy/Sell | kr217.20 | 99.50% |
EQL Pharma AB (publ) Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for EQL Pharma AB (publ) has grown by 260.84%, going from kr72.03M to kr259.91M. According to 0 prominent analysts, EQL Pharma AB (publ)'s Revenue will fall by 19.47% in the next year, reaching kr209.31M. By 2030, professionals believe that EQL Pharma AB (publ)'s Revenue will decrease by 0.29%, reaching kr259.16M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EGTX Stock Forecast | Egetis Therapeutics AB (publ) | Outperform |
7
|
kr6.37 | Buy/Sell | kr11.10 | 88.38% |
| CRNO B Stock Forecast | Cereno Scientific AB (publ) |
0
|
kr4.34 | Buy/Sell | kr1.90 | -56.22% | |
| IBT B Stock Forecast | Infant Bacterial Therapeutics ... | - |
0
|
kr103.50 | Buy/Sell | kr0.00 | -100.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DMYD B Stock Forecast | Diamyd Medical AB (publ) |
9
|
kr9.72 | Buy/Sell | kr19.00 | 69.75% | |
| MOB Stock Forecast | Moberg Pharma AB (publ) |
7
|
kr30.72 | Buy/Sell | kr29.00 | -25.13% | |
| IRLAB A Stock Forecast | IRLAB Therapeutics AB (publ) |
16
|
kr13.20 | Buy/Sell | kr59.00 | 327.65% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ENZY Stock Forecast | Enzymatica AB (publ) |
8
|
kr3.39 | Buy/Sell | kr0.47 | -86.43% | |
| ORX Stock Forecast | Orexo AB (publ) |
6
|
kr16.52 | Buy/Sell | kr25.50 | 36.20% | |
| RLS Stock Forecast | RLS Global AB (publ) | - |
0
|
kr4.98 | Buy/Sell | kr0.00 | -100.00% |
EQL Pharma AB (publ) EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, EQL Pharma AB (publ)'s EBITDA has grown, increasing from kr6.95M to kr45.04M – an increase of 548.06%. For next year, the 1 analysts predict EBITDA of kr127.96M, which would mean an increase of 184.10%. Over the next six years, the pros' prediction is EBITDAof kr90.43M, which would mean a six-year growth forecast of 100.77%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACTI Stock Forecast | Active Biotech AB (publ) |
0
|
kr0.55 | Buy/Sell | kr2.00 | 245.45% | |
| ERMA Stock Forecast | Enorama Pharma AB (publ) | - |
-14
|
kr2.45 | Buy/Sell | kr0.00 | -100.00% |
| INDEX Stock Forecast | InDex Pharmaceuticals Holding ... | Hold |
0
|
kr0.33 | Buy/Sell | kr0.56 | 63.64% |
EQL Pharma AB (publ) EBIT Forecast for 2023 - 2025 - 2030
EQL Pharma AB (publ)'s EBIT has increased by 812.58% In the last three years, going from kr4.53M to kr41.34M. In the next year, analysts expect EBIT to reach kr116.92M – an increase of 182.83%. For the next six years, the forecast is for EBIT to grow by 96.70%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NNH Stock Forecast | New Nordic Healthbrands AB (pu... | - |
0
|
kr19.00 | Buy/Sell | kr0.00 | -100.00% |
| ALZCUR Stock Forecast | AlzeCure Pharma AB (publ) |
0
|
kr2.03 | Buy/Sell | kr14.50 | 565.02% | |
| PILA Stock Forecast | Pila Pharma AB (publ) | - |
0
|
kr1.31 | Buy/Sell | kr0.00 | -100.00% |
EQL Pharma AB (publ) EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, EQL Pharma AB (publ)'s EPS has fallen from kr2.15 to kr0.00 – a 100.00% decrease. In the coming year, analysts are expecting an increase in EPS, predicting it will reach kr3.13 – an increase of 100.00%. Over the next six years, experts anticipate that EPS growth for EQL Pharma AB (publ) will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ISOFOL Stock Forecast | Isofol Medical AB (publ) | - |
6
|
kr0.73 | Buy/Sell | kr0.77 | 5.48% |
| ODI Stock Forecast | ODI Pharma AB (publ) | - |
0
|
kr5.45 | Buy/Sell | kr0.00 | -100.00% |
| PMED Stock Forecast | PEPTONIC medical AB (publ) | - |
4
|
kr0.06 | Buy/Sell | kr0.79 | -100.00% |
.jpg)